|
|
|
Fuad is setting up his profile
-
Describe Yourself:
Fuad El-Hibri
Chairman of the Board of Directors and Chief Executive Officer
Emergent BioSolutions Inc.
Professional Background
Mr. Fuad El-Hibri is the Chairman and Chief Executive Officer of Emergent BioSolutions Inc. (Emergent), a publicly traded biopharmaceutical company focused on developing, manufacturing and commercializing vaccines and therapeutics to prevent and treat life-threatening diseases. The company’s current marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only FDA-licensed vaccine for pre-exposure prophylaxis of anthrax disease. The company is also investing heavily in the development of a broad pipeline of products that address specific global unmet medical needs, including Typhoid, Tuberculosis, Hepatitis B and Chlamydia.
Mr. El-Hibri has extensive experience in the biopharmaceutical industry beginning with Porton Products, Ltd. (Porton), a mid-sized biotechnology company in the United Kingdom. Subsequent to the successful marketing and distribution of Porton’s biodefense vaccines to foreign governments in the early 1990’s, Mr. El-Hibri organized a management buyout of Porton in 1994, forming Speywood Holdings, Ltd. He was appointed to the Board of Directors of Speywood Holdings, Ltd. and acted as an advisor to the senior management team in the operations of the company until 1996.
Starting in the 1990’s, Mr. El-hibri formed and then sold three mobile telecommunications companies, Mobile TeleSystems, serving the greater Moscow region, as well as Digitel and Digicel, serving markets in South and Central America.
Mr. El-Hibri began his career with Citigroup in commercial banking and subsequently in mergers & acquisitions. Following his tenure at Citigroup, Mr. El-Hibri joined Booz Allen & Hamilton as a management consultant in South East Asia, where he led several large client engagements.
|
|
|
